Evidence map›Paper›PMID 39633277›Full record

ArticleMolecular medicine (Cambridge, Mass.)2024

Revisiting the follicle-stimulation hormone receptor expression and function in human myometrium and adipose tissue.

Ewelina Palak, Donata Ponikwicka-Tyszko, Kamila Pulawska-Moon, Maria Sztachelska, Gabriela Milewska, Beata Modzelewska, Tomasz Kleszczewski, Maria L Koivukoski, Piotr Bernaczyk, Hady Razak Hady and 7 more

Abstract read
In one paragraph

Article in Molecular medicine (Cambridge, Mass.), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Article
  3. Activin Actions in Adipocytes.The Journal of clinical endocrinology and metabolism · 2025
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Ewelina Palak *Department of Biology and Pathology of Human Reproduction, Institute of Animal Reproduction and Food Research, Polish Academy of Sciences, Olsztyn, 10-748, Poland.
Donata Ponikwicka-Tyszko *Department of Biology and Pathology of Human Reproduction, Institute of Animal Reproduction and Food Research, Polish Academy of Sciences, Olsztyn, 10-748, Poland.
Kamila Pulawska-MoonInstitute of Biomedicine, Research Centre for Integrative Physiology and Pharmacology, University of Turku, Turku, 20520, Finland.
Maria SztachelskaDepartment of Biology and Pathology of Human Reproduction, Institute of Animal Reproduction and Food Research, Polish Academy of Sciences, Olsztyn, 10-748, Poland.
Gabriela MilewskaDepartment of Reproduction and Gynecological Endocrinology, Medical University of Bialystok, Bialystok, 15-276, Poland.
Beata ModzelewskaDepartment of Biophysics, Medical University of Bialystok, Bialystok, 15-269, Poland.
Tomasz KleszczewskiDepartment of Biophysics, Medical University of Bialystok, Bialystok, 15-269, Poland.
Maria L KoivukoskiInstitute of Biomedicine, Research Centre for Integrative Physiology and Pharmacology, University of Turku, Turku, 20520, Finland.
Piotr BernaczykDepartment of Medical Pathomorphology, Medical University of Bialystok, Bialystok, 15-269, Poland.
Hady Razak Hady1st Clinical Department of General and Endocrine Surgery, Medical University of Bialystok, Bialystok, 15- 269, Poland.
Piotr Gołaszewski1st Clinical Department of General and Endocrine Surgery, Medical University of Bialystok, Bialystok, 15- 269, Poland.
Aleksandra N LupinskaDepartment of Biology and Pathology of Human Reproduction, Institute of Animal Reproduction and Food Research, Polish Academy of Sciences, Olsztyn, 10-748, Poland.
Marek KulikowskiDepartment of Perinatology, Medical University of Bialystok, Bialystok, 15-269, Poland.
Adam LemancewiczDepartment of Perinatology, Medical University of Bialystok, Bialystok, 15-269, Poland.
Ilpo T HuhtaniemiInstitute of Reproductive and Developmental Biology, Imperial College London, London, W12 0NN, UK.
Slawomir WolczynskiDepartment of Biology and Pathology of Human Reproduction, Institute of Animal Reproduction and Food Research, Polish Academy of Sciences, Olsztyn, 10-748, Poland.
Nafis A RahmanInstitute of Biomedicine, Research Centre for Integrative Physiology and Pharmacology, University of Turku, Turku, 20520, Finland. nafis.rahman@utu.fi.

Funding

European Union Executive Agency for Small and Medium size Enterprises Grant Cluster UDA- POIG.05.01.00-005/12-00Finnish National Agency for Education OPH-6112-2023Medical University of Bialystok SUB/1/DN/22/002/1104
6 · The paper itself

Abstract

backgroundExtragonadal follicle-stimulating hormone receptor (FSHR) expression at low levels has been shown in several normal and tumor tissues, including myometrium and adipose tissue. FSH-FSHR signaling in the myometrium has been suggested to regulate uterine contractile activity and the timing of labor. In contrast, FSH-FSHR has been linked to the activation of brown/beige fat thermogenesis in adipose tissue. The issue of extragonadal FSHR expression and its functionality remains contentious within the scientific community, as contradictory findings necessitate further independent and critical analyses. Hereby, we re-investigated the FSHR expression and its functionality in normal non-pregnant (M-NP) and pregnant (N-P) human myometrium, as well as in human visceral (VAT) and subcutaneous (SCAT) adipose tissue (AT).

methodsFSHR expression at mRNA (real-time qPCR, RNAscope in situ hybridization) and protein (immunohistochemical staining) levels in adipose tissue, myometrium, and adipocytes were evaluated. Myometrium and adipocytes were treated with recombinant (rh)FSH to study its effects on functional pathways. Myometrium contractile activity was measured using a force transducer with digital output and the DASYLab software unit. Cyclic adenosine monophosphate (cAMP) production by myometrium explants and adipocytes was measured using a cAMP ELISA Kit. The activation of the AKT pathway in myometrium and adipocytes was analyzed by Western blot analysis.

resultsContrary to previous observations, we found no expression of FSHR at either mRNA or protein levels in M-NP, N-P, VAT, and SCAT. Treatment with recombinant human FSH (rhFSH) showed no effect on cAMP production or phosphorylation of AKT in M-NP, N-P, as well as in VAT and SCAT. rhFSH treatment did not influence contractile activity in M-NP, N-P.

conclusionsThese findings suggest that the FSHR signaling pathway does not regulate myometrial contractility during pregnancy. Additionally, the absence of FSHR expression in both VAT and SCAT implied that FSHR does not play a role in the functional signaling pathways in adipose tissues. In conclusion, our findings contradict earlier data on the involvement of FSH-FSHR signaling in regulating myometrial contractility near term, as well as in adipose tissue function.

Indexed as

Adipose TissueMyometriumReceptors, FSHAdipocytesAdultFemaleFollicle Stimulating HormoneHumansPregnancySignal TransductionUterine ContractionFollicle Stimulating HormoneReceptors, FSHAdipocytesAdipose tissueContractile activityFSHRMyometrium

Identifiers

PMID39633277
PMCPMC11619181

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.